PreciseInhale® is unique within inhaled drug development as a ‘precision dosing’ system. Unlike standard ‘tower testing’ systems, it customizes the individual aerosol dose to individual test animals, achieving exceptionally high-precision and predictive data in the preclinical stages of inhaled drug development.

With this order and upcoming collaboration, ISAB expands its operations and unique technology into the important US market.​ The US is a priority market for ISAB, as the FDA’s latest guidelines increasingly emphasize advanced in vitro methods and dissolution testing for inhaled drugs. These regulatory developments support ISAB’s technology platform, including PreciseInhale® and DissolvIt®, and are driving growing demand for physiologically relevant, animal-sparing test systems.

ISAB CEO Manoush Masarrat: "We are thrilled to secure this significant order and partner with a leading global pharmaceutical company in the US. This marks an exciting expansion of PreciseInhale® into North America, a key market for inhaled drug innovation.”

For more information, please contact:
Manoush Masarrat, CEO
Phone: +46 (0) 73 628 9153
E-mail: manoush.masarrat@inhalation.se

About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.

This disclosure contains information that Inhalation Sciences is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on December 4, 2025 at 11:20.